ZNF562

Across TCGA pan-cancer cohorts, ZNF562 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF562 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZNF562 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF562 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and BRCA are the cancer types where ZNF562 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.280	0.756	<.001	72	view →
UCEC	DFS	Median	II,III,IV	1.000	0.437	.014	30	view →
BRCA	OS	Median	IV	0.106	0.791	<.001	13	view →
ESCA	DFS	Median	III,IV	0.100	0.442	.016	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF562–HNSC (OS)

Open the HNSC breakdown →